Hawkins v. Medtronic, Inc.
62 F. Supp. 3d 1144
E.D. Cal.2014Background
- Plaintiff Gary Hawkins alleges Medtronic’s INFUSE® Bone Graft device caused permanent nerve injury after three off‑label posterior spinal implantations without the LT‑Cage; INFUSE® is a Class III device that received FDA premarket approval for a narrow anterior use with the LT‑Cage.
- Plaintiff pleads theories grounded in (a) fraudulent misrepresentation/fraud in the inducement, (b) negligent misrepresentation, (c) strict products‑liability failure to warn (three variants), and (d) a strict‑liability misrepresentation claim.
- Central factual allegations: Medtronic sponsored/ghostwrote articles, paid opinion leaders and sales reps to promote off‑label use, provided intraoperative advice/dosing, underreported adverse events to FDA, and thereby misled surgeons and the literature about INFUSE® risks.
- Defendants moved to dismiss for failure to state a claim and to strike portions of the complaint as immaterial or scandalous; court previously dismissed design‑defect claim with prejudice and gave leave to amend other claims.
- Court analyzes preemption (express under 21 U.S.C. §360k and implied under Buckman), Rule 9(b) particularity for fraud, and whether state duties (e.g., to report adverse events) run parallel to federal requirements.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Preemption of misrepresentation/fraud claims based on off‑label promotion | Hawkins says claims are based on false/misleading off‑label promotion (parallel to FDCA prohibition of false promotion) so not preempted | Medtronic argues off‑label promotion alone isn’t fraudulent and state claims improperly impose duties beyond federal law | Court: Misrepresentation/fraud claims grounded on false or misleading off‑label promotion are not expressly or impliedly preempted (survive preemption) |
| Rule 9(b) particularity for fraud claims | Hawkins amended to identify articles, authors, dates, sales rep conduct, ghostwriting, and omissions; reliance alleged plausibly | Medtronic contends allegations are still too generalized to meet Rule 9(b) and show surgeon reliance | Court: Amended fraud allegations meet Rule 9(b) as to circumstances; reliance need only meet Rule 8 plausibility and is sufficiently pleaded |
| Strict products‑liability misrepresentation (as a standalone theory) | Hawkins asserts a strict‑liability misrepresentation claim tied to off‑label promotion | Medtronic says California law does not recognize such an independent strict‑liability misrepresentation claim | Court: Dismissed strict products‑liability misrepresentation claim with prejudice (not viable under California law) |
| Failure‑to‑warn variants (overpromotion; misrepresentation during off‑label promotion; failure to report adverse events to FDA) | Hawkins asserts (1) overpromotion nullified warnings, (2) misrepresentations during off‑label promotion constitute failure to warn, (3) failing to report adverse events to FDA prevented physicians from learning risks | Medtronic contends these theories are preempted because FDA PMA sets the exclusive warning requirements and off‑label promotion claims may be impliedly preempted | Court: (1) Overpromotion theory — dismissed with prejudice (would require additional warnings; expressly preempted). (2) Failure‑to‑warn based on misrepresentations during off‑label promotion — preempted. (3) Failure to report adverse events to FDA — survives; California law imposes a parallel duty and causal nexus is plausibly alleged |
Key Cases Cited
- Riegel v. Medtronic, Inc., 552 U.S. 312 (federal PMA express‑preemption framework)
- Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (implied preemption where claim seeks to enforce FDCA duties)
- Lohr, Medtronic, Inc. v. Lohr, 518 U.S. 470 (scope of FDA premarket regulation of devices)
- Ashcroft v. Iqbal, 556 U.S. 662 (plausibility standard for pleadings)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (pleading must be more than speculative)
- Vess v. Ciba‑Geigy Corp. USA, 317 F.3d 1097 (Rule 9(b) particularity for fraud pleadings)
- Perez v. Nidek Co., Ltd., 711 F.3d 1109 (preemption analysis distinguishing suing for versus because of FDCA violations)
- Stengel v. Medtronic, Inc., 704 F.3d 1224 (duty to report to third parties like FDA can satisfy manufacturer’s warning duty)
- Eminence Capital, LLC v. Aspeon, Inc., 316 F.3d 1048 (leave to amend standards)